Simulations Plus (NASDAQ:SLP) (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics. In addition to software sales, Simulations Plus offers consulting services, training and custom model development to support drug discovery and development projects from preclinical through clinical stages.
Founded in 1996 and headquartered in Lancaster, California, Simulations Plus has expanded its global footprint by serving clients across North America, Europe and Asia. The company’s software solutions are used by pharmaceutical and biotech firms, academic institutions and regulatory agencies to optimize formulation strategies, anticipate drug interactions and reduce the time and cost associated with in-lab or in-vivo studies. Over time, Simulations Plus has enhanced its product suite with modules for immunogenicity, absorption modeling and physiologically based pharmacokinetics, reflecting ongoing investment in research and development.
Under the leadership of founder and Chief Executive Officer Walter Woltosz, Simulations Plus maintains a focus on innovation and scientific rigor. The management team combines expertise in pharmacology, computational chemistry and engineering to deliver integrated solutions that help clients make data-driven decisions. By offering regular software updates, customer support and continuing education programs, the company seeks to stay at the forefront of modeling and simulation technologies for the life sciences sector.
